{
    "clinical_study": {
        "@rank": "1475", 
        "arm_group": [
            {
                "arm_group_label": "TCM-700C (low dose)", 
                "arm_group_type": "Experimental", 
                "description": "an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C"
            }, 
            {
                "arm_group_label": "TCM-700C (high dose)", 
                "arm_group_type": "Experimental", 
                "description": "an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double blind, multi-center, placebo controlled, three parallel arms,\n      Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high\n      dose onto the combination treatment (PegIFN plus RBV) for subjects with naive genotype 1 HCV\n      infection.\n\n      This will be demonstrated by a higher sustained virologic response rate, defined as the\n      absence of detectable HCV RNA 24 weeks after the termination of combination treatment,\n      compared with the placebo add-on."
        }, 
        "brief_title": "The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible subjects with written informed consent will be stratified according to their\n      baseline HCV RNA (\u2264800,000 IU/mL versus>800,000 IU/mL), stage of liver fibrosis (METAVIR\n      system fibrosis score of 0 1 versus 2 3).\n\n      During the 48 week Treatment Period and 24 week Follow up Period, subjects will be assessed\n      at regular intervals for efficacy and safety at Weeks 2, 4, 8, 12, 16 and then every 8 weeks\n      thereafter until study completion. If possible, subjects who prematurely discontinue the\n      study during the Treatment Period will have samples taken for hematology, biochemistry and\n      urinalysis in the same week of discontinuation as well as 24 weeks after discontinuation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects who are 20 to 65 years old (inclusive), of either gender and     in\n             any ethnical group in Asia.\n\n          -  Chronic hepatitis C, positive with both antibody to hepatitis C virus (anti HCV) and\n             HCV RNA assays.\n\n          -  Confirmed HCV genotype 1.\n\n          -  Subjects who are indicated to have combination treatment of PegIFN\u03b1 2a and RBV at the\n             discretion of the investigator.\n\n          -  All fertile males and females receiving RBV must be using two forms of effective\n             contraception during treatment with study drugs and 6 months post treatment\n             completion.\n\n          -  Subjects must voluntarily give written informed consent indicating that they\n             understand the purpose of and procedures required for the study and are willing to\n             participate in the study.\n\n          -  Subjects must be able to comply with the assessments during the study.\n\n          -  Subjects must be able to understand study QoL questionnaires.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any IFN \u03b1 or any medicines that contain Cordyceps.\n\n          -  Prior treatment of hepatitis C with any other antiviral or immune modulators.\n\n          -  Investigational therapy administered within 4 weeks, or within a time interval less\n             than at least 5 half lives of the investigational agent, whichever is longer, prior\n             to the first scheduled day of dosing in this study.\n\n          -  Subjects diagnosed with hepatocellular carcinoma (HCC) by biopsy or \u03b1 fetoprotein\n             (AFP) serology and radiology (helical computed tomography [CT] and/or magnetic\n             resonance imaging [MRI]) within 5 years of signing the informed consent form.\n\n          -  Evidence of hepatic decompensation (history or current evidence of ascites, bleeding\n             varices or hepatic encephalopathy).\n\n          -  History or evidence of other liver diseases other than chronic HCV infection.\n\n          -  Subjects with known allergy or hypersensitivity to any ingredient of the study drug\n             or placebo.\n\n          -  Pregnant, planning on becoming pregnant, or breastfeeding female subject or male\n             subject whose partner is pregnant or planning on becoming pregnant.\n\n          -  Subject with any of the following laboratory abnormalities:\n\n               1. Platelet count <90,000/mm3;\n\n               2. Absolute neutrophil count <1500 cells/mm3;\n\n               3. Hemoglobin <12 g/dL for women and <13 g/dL for men;\n\n               4. Creatinine >1.5 mg/dL;\n\n               5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >10 x\n                  upper limit of normal (ULN);\n\n               6. Total serum bilirubin >1.5 x ULN;\n\n               7. Subjects without cirrhosis and AFP >50 ng/mL must have an ultrasound between the\n                  screening and baseline visit with no findings suspicious for HCC.\n\n          -  Medical conditions which are contraindications for PegIFN\u03b1 2a or RBV therapy:\n\n               1. Psychiatric disorders;\n\n               2. Organ transplant (other than cornea or hair transplant or skin graft);\n\n               3. Severe concurrent medical disease such as severe hypertension, significant\n                  coronary heart disease, poorly controlled diabetes mellitus (glycated hemoglobin\n                  A1c [HbA1c] >8.5%), not adequately controlled thyroid dysfunction, chronic\n                  obstructive pulmonary disease, severe infections (bacterial, viral, fungal,\n                  including acute tuberculosis), or hemoglobinopathies (thalassemia major or\n                  sickle cell anemia);\n\n               4. Autoimmune hepatitis or other autoimmune conditions known to be exacerbated by\n                  PegIFN\u03b1 2a and RBV.\n\n          -  History of a severe seizure disorder or current anticonvulsant use.\n\n          -  Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular\n             degeneration) or clinically relevant ophthalmological disorder (e.g., due to diabetes\n             mellitus or hypertension).\n\n          -  Other cases judged by the investigator to be ineligible for participation in the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "598", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890200", 
            "org_study_id": "TCM-700-02-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TCM-700C (low dose)", 
                    "TCM-700C (high dose)", 
                    "Placebo"
                ], 
                "description": "conventional treatment of Hepatitis C", 
                "intervention_name": "Peginterferon alfa-2a", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys"
            }, 
            {
                "arm_group_label": [
                    "TCM-700C (low dose)", 
                    "TCM-700C (high dose)", 
                    "Placebo"
                ], 
                "description": "conventional treatment of Hepatitis C", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Rebetol"
            }, 
            {
                "arm_group_label": [
                    "TCM-700C (low dose)", 
                    "TCM-700C (high dose)"
                ], 
                "description": "An add-on drug to conventional treatment of Hepatitis C", 
                "intervention_name": "TCM-700C", 
                "intervention_type": "Drug", 
                "other_name": "TCM-700C"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo, without acting ingredient.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo, without acting ingredient."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "add-on treatment", 
            "botanical drug", 
            "HCV genotype 1", 
            "TCM-700C"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100044"
                    }, 
                    "name": "Peking University People's Hospit"
                }, 
                "investigator": {
                    "last_name": "Lai Wei, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "issheen.jks@gmail.com", 
                    "last_name": "I-Shyan Sheen, MD", 
                    "phone": "+886-968-372-340"
                }, 
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }, 
                    "name": "Chang Gung Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "I-Shyan Sheen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection", 
        "overall_contact": {
            "email": "emilyma@tcmbio.com", 
            "last_name": "Hsiao-Tien Ma", 
            "phone": "+886-2-2658-1677", 
            "phone_ext": "720"
        }, 
        "overall_contact_backup": {
            "email": "yachunwang@tcmbio.com", 
            "last_name": "Ya-Chun Wang, Ph.D", 
            "phone": "+886-2-2658-1677", 
            "phone_ext": "733"
        }, 
        "overall_official": [
            {
                "affiliation": "Chang Gung Memorial Hospital", 
                "last_name": "I-Shyan Sheen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Peking University People's Hospital", 
                "last_name": "Lai Wei, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "sustained virologic response (SVR) rate", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after the end of treatment (EOT, 48 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Virologic response (VR)", 
                "safety_issue": "No", 
                "time_frame": "at the EOT (48 weeks)"
            }, 
            {
                "description": "undetectable HCV RNA at the EOT followed by a positive HCV RNA level within 24 weeks after the EOT", 
                "measure": "relapse rate", 
                "safety_issue": "No", 
                "time_frame": "24 weeks after the EOT"
            }
        ], 
        "source": "TCM Biotech International Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TCM Biotech International Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}